Catalyst Wire Dossier Catalyst Wire Dossier

GSK2282512A (Quadrivalent Influenza Vaccine)

· GlaxoSmithKline
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GSK2282512A (Quadrivalent Influenza Vaccine), covering 2016-04-12 to 2016-04-12. Get the full timeline:

Most recent: Clinical Trial Update: Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age [Phase 3]

See pricing